Tarlatamab treatment

DRUG2 trials

Sponsors

Jonsson Comprehensive Cancer Center, University Hospital, Strasbourg, France

Conditions

Advanced TumorsDLL3-expressing TumorsDiagnosis of Neuro-endocrine Carcinoma of the Gynecological Tract

Phase 2

Tarlatamab in Advanced Delta-like 3 (DLL3)-Expressing Tumors Including Neuroendocrine Neoplasms

Active, not recruitingNCT06788938

Jonsson Comprehensive Cancer CenterAdvanced Tumors, DLL3-expressing Tumors

Start: 2025-03-21End: 2029-04-24Target: 29Updated: 2026-09-01

Tarlatamab in Recurrent Gynecological Neuroendocrine Carcinomas: A Phase II Proof-of-concept Study

Not yet recruitingNCT07788365

University Hospital, Strasbourg, FranceDiagnosis of Neuro-endocrine Carcinoma of the Gynecological Tract

Start: 2027-01-15End: 2030-08-31Target: 20Updated: 2026-08-26

Related Papers

A phase 2 basket trial of tarlatamab in patients with advanced DLL3-expressing tumors: University of California Lung Cancer Consortium UCCC-01/UCLA L-10.

Journal of Clinical Oncology2025-05-28